N,N’,N”-tripropylmelamine | 16268-94-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: N,N’,N”-tripropylmelamine
• 英文别名: N,N',N''-tripropyl-[1,3,5]triazine-2,4,6-triamine；N2,N4,N6-tripropyl-melamine；2,4,6-Tris-propylamino-s-triazin；2-N,4-N,6-N-tripropyl-1,3,5-triazine-2,4,6-triamine
• CAS: 16268-94-3
• 化学式: C₁₂H₂₄N₆
• 分子量: 252.363
• InChiKey: APSYKKQDFLXLLX-UHFFFAOYSA-N

物化性质

• 沸点：
  413.3±28.0 °C(Predicted)
• 密度：
  1.114±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  74.8
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  Amino(propylimino)methanesulfonic acid 在 叔丁胺 作用下， 生成 N,N’,N”-tripropylmelamine
  参考文献：
  名称：

  Maryanoff, Cynthia A.; Stanzione, Robin C.; Plampin, James N., Phosphorus and Sulfur and the Related Elements, 1986, vol. 27, p. 221 - 232

  摘要：

  DOI：

文献信息

• Design, Synthesis, and in Vitro Biological Evaluation of Small Molecule Inhibitors of Estrogen Receptor α Coactivator Binding
  作者：Alice L. Rodriguez、Anobel Tamrazi、Margaret L. Collins、John A. Katzenellenbogen

  DOI：10.1021/jm030404c

  日期：2004.1.1

  interaction was not with the ligand binding pocket. The most effective CBIs were those from the pyrimidine family, the best binding with K(i) values of ca. 30 microM. The trithiane- and cyclohexane-based CBIs appear to be poor structural mimics, because of equatorial vs axial conformational constraints, and the triazene-based CBIs are also conformationally constrained by amine-substituent-to-ring resonance

  与激动剂配体复合的核受体（NRs）通过募集共激活蛋白复合物来激活转录。原则上，应该使用适当设计的共激活因子结合抑制剂（CBI）直接阻止这种转录关键受体-共激活因子的相互作用，从而抑制NRs的转录活性。为了指导我们各种CBI的设计，我们使用了激动剂结合的雌激素受体（ER）配体结合结构域（LBD）的晶体结构，该结构与含有LXXLL签名基元并结合到表面疏水槽的助活化剂肽复合的LBD。一组基于从外而内的设计方法的CBI，具有各种杂环核心（三氮烯，嘧啶，三硫杂环己烷，环己烷），它们模仿肽螺旋上三个亮氨酸的系链位点，在其上连接有亮氨酸残基样取代基。另一组基于“由内而外”的方法，具有一个萘核，该萘核模拟两个最深埋的亮氨酸，其取代基向外延伸，以模拟共活化剂螺旋肽的其他特征。开发了一种基于荧光各向异性的共激活剂竞争测定法，以测量这些CBI与ER激动剂复合物与共激活剂相互作用的凹槽位点的特异性结合。对照配体结
• [EN] METHOD FOR ALKYLATING AN AMINO COMPOUND<br/>[FR] PROCÉDÉ D'ALKYLATION D'UN COMPOSÉ AMINÉ
  申请人：BOREALIS AGROLINZ MELAMINE

  公开号：WO2018096011A1

  公开（公告）日：2018-05-31

  The invention relates to a method for alkylating an amino compound, characterized in that at least one triazine derivative of general formula (I) or at least one urea or urea derivative of the general formula (II), (II), wherein • R4 and R5 mean independently from each other Q1 or a moiety of the formula R6-N-R7 or R8-N-R9 bound with its central nitrogen atom to the triazine ring of the structure of formula (I), whereat - Q1 means a linear or branched C1-C30-alkyl or a cyclic substituent in form of a C5-C20-cycloalkyl, a C5-C20-aryl, a C1-C20-alkylsubstituted C5-C20-aryl or an amide of a cyclic unsaturated carboxylic acid, whereat the C1-C30-alkyl or the cyclic substituent can be interrupted by one or multiple oxygen atoms, sulphur atoms, substituted nitrogen atoms and/or by one or multiple groups of the type –C(O)O-,-OC(O)-,-C(O)- and/or –OC(O)O-, • R1, R2, R3, R6, R7, R8 and R9 mean independently from each other H, linear or branched C1-C20-alkyl, C5-C20-cyclo alkyl, C5-C20-aryl, C1-C20-alkylsubstituted C5-C20-aryl, which in each case can be interrupted by one or multiple oxygen atoms, sulphur atoms and/or substituted nitrogen atoms and/or by one or multiple groups of the type –C(O)O-, - OC(O)-, -C(O)- and/or –OC(O) O- and/or can be functionalized by one or multiple hydroxyl groups and/or mercapto groups, and • X means O or S, is reacted with at least one alcohol of the general formula (III) R10-OH wherein R10 means a linear or branched C1-C20-alkyl, C5-C20-cycloalkyl, or C1-C20- alkylsubstituted C5-C20-aryl, which can be in each case interrupted by one or multiple oxygen atoms, sulphur atoms, substituted nitrogen atoms and/or by one or multiple groups of the type –C(O)O-, -OC(O)-, -C(O)- and/or –OC(O)O- and/or can be functionalized by one or multiple hydroxyl groups and/or mercapto groups, wherein the reaction is carried out in the presence of at least one Ruthenate of the general formula (IV) Mn(RuO4) and/or at least one Perruthenate of the general formula (V) M(RuO4)n wherein the cation M is selected from a group comprising an alkali, earth alkali or substituted or non-substituted ammonium cation.

  本发明涉及一种烷基化氨基化合物的方法，其特征在于至少使用一种通式(I)的三嗪衍生物或至少使用一种通式(II)的脲或脲衍生物，其中•R4和R5分别独立地表示Q1或式R6-N-R7或R8-N-R9的基团，其中心氮原子与通式(I)的三嗪环结构相连，其中-Q1表示线性或支链的C1-C30烷基或形式为C5-C20环烷基，C5-C20芳基，C1-C20烷基取代的C5-C20芳基或环状不饱和羧酸酰胺的取代基，其中C1-C30烷基或环状取代基可以被一个或多个氧原子，硫原子，取代的氮原子和/或一个或多个-C(O)O-，-OC(O)-，-C(O)-和/或-OC(O)O-类型的基团所中断，•R1，R2，R3，R6，R7，R8和R9分别独立地表示H，线性或支链的C1-C20烷基，C5-C20环烷基，C5-C20芳基，C1-C20烷基取代的C5-C20芳基，其中每种情况都可以被一个或多个氧原子，硫原子和/或取代的氮原子和/或一个或多个-C(O)O-，-OC(O)-，-C(O)-和/或-OC(O)O-类型的基团所中断，并且可以通过一个或多个羟基和/或巯基进行官能化，•X表示O或S，与至少一种通式(III)的醇反应，通式(III)为R10-OH，其中R10表示线性或支链的C1-C20烷基，C5-C20环烷基或C1-C20烷基取代的C5-C20芳基，每种情况都可以被一个或多个氧原子，硫原子，取代的氮原子和/或一个或多个-C(O)O-，-OC(O)-，-C(O)-和/或-OC(O)O-类型的基团所中断，并且可以通过一个或多个羟基和/或巯基进行官能化，其中在至少一种Mn（RuO4）的通式（IV）钌酸盐和/或至少一种M（RuO4）n的通式（V）高钒酸盐的存在下进行反应，其中阳离子M选择自碱金属，碱土金属或取代或未取代的铵阳离子组成的群。
• Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
  申请人：Mannion James C.

  公开号：US20120295911A1

  公开（公告）日：2012-11-22

  The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.

  本发明包括用于治疗需要呼吸控制疾病或障碍的受体的组合物。本发明还包括一种治疗需要呼吸系统疾病或障碍的受体的方法，包括向受体施用本发明的药物制剂的治疗有效量。本发明还包括一种预防或稳定需要呼吸节律的受体的方法，包括向受体施用本发明的药物制剂的治疗有效量。
• COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS
  申请人：Acucela Inc.

  公开号：US20140228443A1

  公开（公告）日：2014-08-14

  Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.

  提供了化合物、药物组合物及使用该化合物和组合物治疗眼科疾病和疾病的方法，例如年龄相关性黄斑退化和斯塔加德病。
• NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES
  申请人：GALLEON PHARMACEUTICALS, INC.

  公开号：US20140371224A1

  公开（公告）日：2014-12-18

  The present invention includes compounds, and compositions comprising the same, that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention.

  本发明包括化合物及其组合物，适用于治疗需要治疗呼吸控制疾病或障碍的患者。本发明还包括一种治疗需要治疗呼吸系统疾病或障碍的患者的方法，包括向患者施用本发明中化合物的治疗有效量。本发明还包括一种预防或稳定需要稳定呼吸节律的患者的方法，包括向患者施用本发明中化合物的治疗有效量。